<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2380">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03075904</url>
  </required_header>
  <id_info>
    <org_study_id>SYNT001-103</org_study_id>
    <nct_id>NCT03075904</nct_id>
  </id_info>
  <brief_title>A Safety Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)</brief_title>
  <official_title>A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects With Chronic Pemphigus (Vulgaris or Foliaceus)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syntimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syntimmune, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the safety, tolerability, pharmacokinetics (PK),
      pharmacodynamics (PD), immunogenicity, and effects on pemphigus disease activity markers of
      intravenous (IV) SYNT001.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety data (counts and percentages of adverse events)</measure>
    <time_frame>Day 0 - Day 56</time_frame>
    <description>counts and percentages of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (serum concentration of SYNT001)</measure>
    <time_frame>Day 0, 1, 2, 5, 28, 29, 30, 33</time_frame>
    <description>serum concentration of SYNT001</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pemphigus Disease Area Index (PDAI)</measure>
    <time_frame>Day 0, 7, 14, 28, 33, 42, 56</time_frame>
    <description>disease activity marker</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Pemphigus</condition>
  <condition>Pemphigus Vulgaris</condition>
  <condition>Pemphigus Foliaceus</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYNT001 Dose 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SYNT001 Dose 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYNT001</intervention_name>
    <description>IV in 250 mL over 1 hour administered on Day 0, 7, 14, 21, and 28</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects must meet the following criteria to be included:

          -  Willing and able to read, understand and sign an informed consent form

          -  Documented diagnosis of pemphigus vulgaris or foliaceus

          -  Must use medically acceptable contraception

        Exclusion Criteria:

        Subjects meeting any of the following criteria are to be excluded:

          -  Subject unable or unwilling to comply with the protocol

          -  Active non-hematologic malignancy or history of non-hematologic malignancy in the 3
             years prior to screening (exclusive of non-melanoma skin cancer and cervical cancer
             in situ)

          -  Positive for HIV or hepatitis C antibody

          -  Positive for hepatitis B surface antigen

          -  IVIG use within 60 days of screening

          -  Any exposure to an investigational drug or device within the 30 days prior to
             screening

          -  Plasmapheresis or immunoadsorption within 60 days of screening

          -  Subject has any current medical condition that, in the opinion of the Investigator,
             may compromise their safety or compliance, preclude successful conduct of the study,
             or interfere with interpretation of the results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Syntimmune, Inc</last_name>
    <email>SYNT001Clinical@syntimmune.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 8, 2017</lastchanged_date>
  <firstreceived_date>March 6, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pemphigus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
